JAKARTA. PT Medela Potentia Tbk (MDLA), a healthcare company that will hold an Initial Public Offering (IPO), has collaborated with more than 70 principals to support its business portfolio.

Specifically for pharmaceutical products, MDLA has collaborated with 25 principals, with a total of 1,800 SKUs (Stock Keeping Units). Some of the main principals of the company's pharmaceutical products include DexaMedica, Pfizer, Bayer, Novo Nordisk, and Phapros.

In the healthcare segment, MDLA has collaborated with 25 principals and has sold around 2,000 SKUs. Some of the key principals that support the company's health product sales include Actavis, Sari Sehat, Youvit, Nestle, Bayer, L'OREAL, and Purina.

Lastly, in the medical devices segment, MDLA has sold more than 5,300 products from 26 principals. Some of the principals the company has worked with include Rossmax, SD Biosensor, Johnson & Johnson, IDL Biotech, and Medtronic.

The duration of MDLA's cooperation with all principals is quite varied, ranging from 2 years to decades.

Pharmaceutical products accounted for IDR7.46 trillion or 69.2% of MDLA's total sales, as of 30 September 2024. Meanwhile, health products contributed IDR2.07 trillion or 19.2% and medical devices IDR1.26 trillion or 11.7%.

As previously reported by IDNFinancials.com, MDLA is aiming to raise up to IDR 805 billion from its IPO. This corporate action involves offering 3.5 billion new shares, equivalent to 25% of the company's total shares. (KR)